LABU a 3X leveraged ETF of biotechnology stocks LONG

2024年2月26日

LABU on a 240-minute chart has been in a trend up gaining 100% in 3 months. Both the fast and

slow ( green and red) are above the 50 level. Biotechnology is expected to be a hot subsector

this year as healthcare recovered further from the COVID pandemic anything from startups to

big pharma- from vaccines to new drugs for diabetes, liver disease and obesity. Leveraged

funds have time decay from the leveraging and management fees and are meant to be for

short-term trading. Nonetheless, 100% in 3 months is an excellent return. I add to my position

when I see a pullback on the 15-30 minute chart. If price rises more than 2% in a day I may

take 1-2 shares off the position to realize some profit and recycle ( compound) into the next

buy. According to those that follow sectors, LABU should outperform this year.

2024年2月27日

交易進行

Not unexpectedly LABU had a surge, 10% of the position closed to buy a single call option contract for LLY and another for NVAX, and another for MRNA. The latter heavily beat on the earnings report. Will deploy fresh capital into LABU upon
a dip down into the support of the liquidity-adjusted moving average cloud. Rinse
and repeat.